[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-b1589c70-7cb5-4421-a02e-d426031ca550--":3,"related-articles-undefined-undefined-59fab0db-f039-41c3-b159-33eb110c7d02-true":355},{"id":4,"type":5,"title":6,"pubDate":7,"logoUrl":8,"organisationTitle":9,"thirdParty":10,"body":11,"imageUrls":12,"city":14,"website":15,"orgId":16,"branches":17,"description":354},"b1589c70-7cb5-4421-a02e-d426031ca550","PRESSRELEASE","'Slechts twee derde nieuwe medicijnen bereikt Nederlandse patiënten'","2021-05-25T15:37:02.545+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F59fab0db-f039-41c3-b159-33eb110c7d02\u002F71d6fa60-ea5d-4762-a6ea-4fac82c58712.jpg","ANP Expert Support",false,"\u003Cp>\u003Cstrong>Dit is een expertquote van Gerard Schouw, Vereniging Innovatieve Geneesmiddelen, in het kader van ANP Expert Support. U kunt dit bericht, of delen hiervan gebruiken op uw kanalen. Aanleiding: \u003Cstrong>Lancering rapport over lengte wachttijd voor geneesmiddelen en vaccins na goedkeuring EMA | ANP\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Snelle, goede beschikbaarheid van nieuwe medicijnen is ontzettend belangrijk voor de duizenden Nederlandse patiënten die er om zitten te springen. En wat blijkt uit de Patients WAIT Indicator, een jaarlijks onafhankelijk onderzoek naar de beschikbaarheid van nieuwe, toegelaten medicijnen: Nederland loopt flink achter op koploper Duitsland. Van de 152 onderzochte nieuwe medicijnen die zijn toegelaten tot de Europese markt zijn er in Duitsland inmiddels 133 beschikbaar, maar in ons land slechts 96.\u003C\u002Fp>\n\u003Cp>Daarmee komt Nederland op de achtste positie in de Patients W.A.I.T. Indicator, waarin 34 Europese landen zijn betrokken. Ook Denemarken, Oostenrijk, Zwitserland, Italië, Engeland en Frankrijk scoren beter dan Nederland.\u003C\u002Fp>\n\u003Cp>Bij medicijnen voor kanker en zeldzame ziekten is het beeld voor de Nederlandse patiënt nog iets slechter. In die categorieën eindigt ons land respectievelijk op een negende en tiende positie.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Dalende trend\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Het onderzoek, uitgevoerd door IQVIA, richtte zich op medicijnen die van 2016 tot en met 2019 een EMA-goedkeuring kregen. De trend is niet gunstig. In het vorig jaar gepubliceerde onderzoek was nog 67% van de nieuwe medicijnen beschikbaar voor de Nederlandse patiënt. Dat percentage is nu gedaald naar 63%.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Analyseren\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>De hamvraag is dus: wat kunnen we leren van Duitsland? Dat we steeds langzamer lijken te worden, is slecht nieuws voor duizenden patiënten voor wie snelle beschikbaarheid juist belangrijk is. Samen met een nieuw kabinet, het Zorginstituut Nederland en artsen moeten we analyseren waar precies de knelpunten zitten. En wat haalbare oplossingen zijn. Daarover gaan we graag in gesprek met. Dit kunnen we alleen in constructieve samenwerking verbeteren.\u003C\u002Fp>\n\u003Cp>\u003Cem>Gerard Schouw is directeur van Vereniging Innovatieve Geneesmiddelen\u003C\u002Fem>\u003C\u002Fp>",[13],"https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F59fab0db-f039-41c3-b159-33eb110c7d02\u002Fb1589c70-7cb5-4421-a02e-d426031ca550\u002FPatientWAITIndicator2021.pdf","Den Haag","https:\u002F\u002Fexpertquotes.anp.nl\u002Fhome\u002Fdetail\u002F8c768130-186b-417b-8db1-3c45f96f2b95\u002Ftitle\u002Fslechts-twee-derde-nieuwe-medicijnen-bereikt-nederlandse-patienten","59fab0db-f039-41c3-b159-33eb110c7d02",[18,22,25,28,31,34,37,40,43,46,49,52,55,58,61,64,67,70,73,76,79,82,85,88,91,94,97,100,104,107,110,113,116,119,122,125,128,131,134,137,140,143,146,148,151,154,157,160,163,166,169,172,175,178,181,184,187,190,193,196,199,202,205,208,211,214,217,220,223,226,229,232,235,238,241,244,247,250,253,256,259,262,265,268,271,274,277,280,283,287,290,293,296,299,302,305,308,311,314,317,320,323,327,330,333,336,339,342,345,348,350],{"id":19,"title":20,"parentId":21},"29183","Medisch specialisme","29100",{"id":23,"title":24,"parentId":21},"29127","Aflevering van geneesmiddelen",{"id":26,"title":27,"parentId":21},"29186","Afslanken en dieetleer",{"id":29,"title":30,"parentId":21},"29102","Alcoholisme en drugsmisbruik",{"id":32,"title":33,"parentId":21},"29103","Allergologie",{"id":35,"title":36,"parentId":21},"29104","Alternatieve geneeskunde",{"id":38,"title":39,"parentId":21},"29105","Ambulancediensten",{"id":41,"title":42,"parentId":21},"93242","Andrologie",{"id":44,"title":45,"parentId":21},"29106","Anesthesie",{"id":47,"title":48,"parentId":21},"93172","Aromatherapie",{"id":50,"title":51,"parentId":21},"29118","Gezondheidszorg",{"id":53,"title":54,"parentId":21},"29109","Bio-informatica",{"id":56,"title":57,"parentId":21},"29111","Cardiologie",{"id":59,"title":60,"parentId":21},"29114","Chiropodie",{"id":62,"title":63,"parentId":21},"29115","Chiropraxie",{"id":65,"title":66,"parentId":21},"29190","Chirurgie",{"id":68,"title":69,"parentId":21},"29119","Computers in gezondheidszorg",{"id":71,"title":72,"parentId":21},"29122","Dermatologie",{"id":74,"title":75,"parentId":21},"29126","Geneesmiddelen",{"id":77,"title":78,"parentId":21},"29123","Diabetes",{"id":80,"title":81,"parentId":21},"29124","Diagnostiek",{"id":83,"title":84,"parentId":21},"29135","Eerste hulp",{"id":86,"title":87,"parentId":21},"29128","Eetstoornissen",{"id":89,"title":90,"parentId":21},"29129","Endocrinologie",{"id":92,"title":93,"parentId":21},"29130","Epidemiologie",{"id":95,"title":96,"parentId":21},"29131","Experimentele geneeskunde",{"id":98,"title":99,"parentId":21},"29134","Huisartsen",{"id":101,"title":102,"parentId":103},"29136","Fitness","49100",{"id":105,"title":106,"parentId":21},"29175","Fysiologie",{"id":108,"title":109,"parentId":21},"29176","Fysiotherapie",{"id":111,"title":112,"parentId":21},"29137","Gastro-enterologie",{"id":114,"title":115,"parentId":21},"29120","Gehoor en spraak",{"id":117,"title":118,"parentId":21},"29159","Geneeskunde",{"id":120,"title":121,"parentId":21},"29113","Geneeskunde bij ongevallen",{"id":123,"title":124,"parentId":21},"29160","Geneeskunde en uitrusting in het buitenland",{"id":126,"title":127,"parentId":21},"29179","Geneesmiddelen op voorschrift",{"id":129,"title":130,"parentId":21},"29139","Gerontologie",{"id":132,"title":133,"parentId":21},"29132","Gezinsplanning",{"id":135,"title":136,"parentId":21},"29141","Gezondheid",{"id":138,"title":139,"parentId":21},"29200","Gezondheidsbeheer",{"id":141,"title":142,"parentId":21},"93782","Gezondheidsbeleid",{"id":144,"title":145,"parentId":21},"29142","Gezondheidsonderwijs",{"id":147,"title":51,"parentId":21},"29143",{"id":149,"title":150,"parentId":21},"29101","HIV en AIDS",{"id":152,"title":153,"parentId":21},"29140","Hematologie",{"id":155,"title":156,"parentId":21},"29144","Holistische geneeskunde",{"id":158,"title":159,"parentId":21},"29145","Homeopathie",{"id":161,"title":162,"parentId":21},"29138","Mantelzorg",{"id":164,"title":165,"parentId":21},"29148","Hypnose",{"id":167,"title":168,"parentId":21},"29149","Immunologie",{"id":170,"title":171,"parentId":21},"29151","Intensive care",{"id":173,"title":174,"parentId":21},"29125","Invaliditeit en revalidatie",{"id":176,"title":177,"parentId":21},"29173","Keel-, neus- en oorheelkunde",{"id":179,"title":180,"parentId":21},"29116","Klinische geneeskunde",{"id":182,"title":183,"parentId":21},"29117","Klinische testen",{"id":185,"title":186,"parentId":21},"29107","Kunstmatige weefsels",{"id":188,"title":189,"parentId":21},"29152","Leverziekten",{"id":191,"title":192,"parentId":21},"29153","Longziekten",{"id":194,"title":195,"parentId":21},"93772","Medicijnenbeleid",{"id":197,"title":198,"parentId":21},"29154","Medische en ziekenhuisuitrusting",{"id":200,"title":201,"parentId":21},"94192","Medische esthetiek",{"id":203,"title":204,"parentId":21},"29157","Medische producten en diensten",{"id":206,"title":207,"parentId":21},"29155","Medische specialisten",{"id":209,"title":210,"parentId":21},"29158","Medische technologie",{"id":212,"title":213,"parentId":21},"29156","Medische-praktijkbeheer",{"id":215,"title":216,"parentId":21},"29161","Mentale gezondheid",{"id":218,"title":219,"parentId":21},"29163","Nefrologie",{"id":221,"title":222,"parentId":21},"29164","Neurologie",{"id":224,"title":225,"parentId":21},"29166","Nucleaire geneeskunde",{"id":227,"title":228,"parentId":21},"29169","Obstetrie en gynaecologie",{"id":230,"title":231,"parentId":21},"29150","Onafhankelijke gezondheidssector",{"id":233,"title":234,"parentId":21},"29110","Oncologie",{"id":236,"title":237,"parentId":21},"94822","Oogverzorging",{"id":239,"title":240,"parentId":21},"94802","Optica",{"id":242,"title":243,"parentId":21},"29170","Opticiens en oftalmologie",{"id":245,"title":246,"parentId":21},"94812","Optische technologie",{"id":248,"title":249,"parentId":21},"29171","Orthopedie",{"id":251,"title":252,"parentId":21},"29172","Ostheopathie",{"id":254,"title":255,"parentId":21},"29112","Ouderenzorg",{"id":257,"title":258,"parentId":21},"29174","Kindergeneeskunde",{"id":260,"title":261,"parentId":21},"29177","Plastische chirurgie",{"id":263,"title":264,"parentId":21},"29180","Psychiatrie en psychotherapie",{"id":266,"title":267,"parentId":21},"29181","Radiologie en radiografie",{"id":269,"title":270,"parentId":21},"29184","Reumatologie",{"id":272,"title":273,"parentId":21},"29182","Langdurige zorg",{"id":275,"title":276,"parentId":21},"29108","Rugpijn",{"id":278,"title":279,"parentId":21},"29188","SOA's",{"id":281,"title":282,"parentId":21},"29185","Seksuele gezondheid",{"id":284,"title":285,"parentId":286},"93162","Wellness","91000",{"id":288,"title":289,"parentId":21},"29187","Sportgeneeskunde",{"id":291,"title":292,"parentId":21},"29189","Stressbeheer",{"id":294,"title":295,"parentId":21},"29121","Tandheelkunde",{"id":297,"title":298,"parentId":21},"29191","Telegeneeskunde",{"id":300,"title":301,"parentId":21},"29165","Toepassingen voor nieuwe geneesmiddelen",{"id":303,"title":304,"parentId":21},"29192","Toxicologie",{"id":306,"title":307,"parentId":21},"29193","Transplantaties",{"id":309,"title":310,"parentId":21},"29194","Traumatologie",{"id":312,"title":313,"parentId":21},"93232","Tropische ziekten",{"id":315,"title":316,"parentId":21},"29195","Urologie",{"id":318,"title":319,"parentId":21},"29196","Vaccins",{"id":321,"title":322,"parentId":21},"29167","Verpleegkundigen",{"id":324,"title":325,"parentId":326},"29198","Vitamines en voedingssupplementen","13100",{"id":328,"title":329,"parentId":326},"29168","Voeding",{"id":331,"title":332,"parentId":21},"29162","Vroedvrouwen",{"id":334,"title":335,"parentId":21},"29133","Vruchtbaarheid en voortplanting",{"id":337,"title":338,"parentId":21},"29199","Yoga",{"id":340,"title":341,"parentId":21},"29146","Ziekenhuisartsen",{"id":343,"title":344,"parentId":21},"29147","Ziekenhuizen",{"id":346,"title":347,"parentId":21},"29178","Zwangerschap",{"id":21,"title":349},"Zorg",{"id":351,"title":352,"parentId":353},"41108","Overheid","41100","Dit is een expertquote van Gerard Schouw, Vereniging Innovatieve Geneesmiddelen, in het kader van ANP Expert Support. U kunt dit bericht, of delen hiervan gebru",[356,364,373,382,391,400,407,416,425,432],{"id":357,"title":358,"pubDate":359,"logoUrl":360,"thirdParty":10,"orgId":16,"branches":361,"description":363},"54485858-9222-49c1-8d2e-c1596148fc3b","Podcast: 'Europa is aan zet en moet wetgeving levensreddende AED's beter regelen'","2025-11-13T09:27:46.952+01:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F59fab0db-f039-41c3-b159-33eb110c7d02\u002Feafd4677-002e-45b1-bc57-6f0ce3629385.jpg",[362],{"id":21,"title":349},"Zestig procent van de AED's in Europa functioneert niet naar behoren. Nederland heeft qua hulpverlening een van de beste infrastructuren ter wereld, maar in hee",{"id":365,"title":366,"pubDate":367,"logoUrl":360,"thirdParty":10,"orgId":16,"branches":368,"description":372},"b4bcc094-eb40-4a4f-9f44-d3367e5e7ac9","Podcast: 'Onderwijs moet studenten voorbereiden op wereld waar AI een cruciale rol speelt'","2025-11-11T09:32:10.072+01:00",[369],{"id":370,"title":371},"19100","Onderwijs","Steeds meer leraren gebruiken kunstmatige intelligentie (AI) in de klas, maar velen zijn ook nog huiverig. Want leidt AI niet tot meer fraude? En hoe leer je je",{"id":374,"title":375,"pubDate":376,"logoUrl":360,"thirdParty":10,"orgId":16,"branches":377,"description":381},"7637cc8d-dcd5-4117-825d-67782719053b","Podcast: 'Veel leidinggevenden maken fout om politieke spanningen op werk te vermijden'","2025-11-04T10:13:49.427+01:00",[378],{"id":379,"title":380},"12109","Arbeidsmarkt en ondernemen","Met de historische verkiezingsuitslag is niet alleen in politiek Den Haag de verdeeldheid groot, ook op de werkvloer dreigt polarisatie. Want wat moet je doen a",{"id":383,"title":384,"pubDate":385,"logoUrl":360,"thirdParty":10,"orgId":16,"branches":386,"description":390},"d3c30dcc-bdd2-4914-ba44-322b28204c5d","Podcast: 'Verpakkingswet laat zien dat Europese milieuwetgeving wel succesvol kan zijn'","2025-10-14T09:36:35.743+02:00",[387],{"id":388,"title":389},"23100","Klimaat, milieu en duurzaamheid","Europese milieuwetgeving staat steeds meer onder druk. Veel bedrijven vinden die wetgeving te ingewikkeld en vanuit de internationale gemeenschap lijkt er steed",{"id":392,"title":393,"pubDate":394,"logoUrl":360,"thirdParty":10,"orgId":16,"branches":395,"description":399},"cdffacd3-e2de-4bcf-9d7f-54dfbd34a8e0","Podcast: 'Risico nemen op stroomnet voorkomt miljardenschade door netcongestie'","2025-10-09T09:47:03.693+02:00",[396],{"id":397,"title":398},"27100","Energie en brandstoffen","De problemen op het stroomnet zijn nog groter dan gedacht. In een Kamerbrief waarschuwt demissionair minister Hermans dat steeds meer bedrijven moeten wachten o",{"id":401,"title":402,"pubDate":403,"logoUrl":360,"thirdParty":10,"orgId":16,"branches":404,"description":406},"c7c009bb-a503-4b31-9179-86c3daf8d41a","Podcast: 'Automatisering heeft averechts effect als medewerkers niet worden betrokken'","2025-06-05T10:18:55.842+02:00",[405],{"id":379,"title":380},"Uit nieuwe CBS-cijfers blijkt dat twee derde van de ondernemers te maken heeft met een personeelstekort. Om daarmee om te gaan zetten ze vooral in op het verbet",{"id":408,"title":409,"pubDate":410,"logoUrl":360,"thirdParty":10,"orgId":16,"branches":411,"description":415},"5380c3cc-47c2-485c-b62f-0f522b769d79","Podcast: 'Onderscheid tussen BNP en brede welvaart staat gelijkheid in de weg'\t","2025-05-22T11:56:49.305+02:00",[412],{"id":413,"title":414},"26100","Economie en geld","Uit nieuwe CBS-cijfers blijkt dat Nederlanders best gelukkig zijn. Maar de hoge kwaliteit van leven blijft ten koste gaan van latere generaties. In de podcast V",{"id":417,"title":418,"pubDate":419,"logoUrl":360,"thirdParty":10,"orgId":16,"branches":420,"description":424},"a8eb400d-5395-42db-b3e3-bf5e83a01c6e","Podcast: 'AI maakt financiële afdeling waardevoller voor bedrijven'","2025-05-08T12:19:34.615+02:00",[421],{"id":422,"title":423},"16100","IT, tech en social media","Twee op de vijf financieel medewerkers zijn bang dat AI hun baan uiteindelijk overbodig maakt, blijkt uit onderzoek van softwaremaker Onguard. In de podcast Ver",{"id":426,"title":427,"pubDate":428,"logoUrl":360,"thirdParty":10,"orgId":16,"branches":429,"description":431},"5a2c5cca-374d-4d0c-ae32-2eb3c630c434","Podcast: 'Cijfers over krapte arbeidsmarkt zeggen weinig, kijk naar wervingshaalbaarheid'","2025-05-01T15:31:28.690+02:00",[430],{"id":379,"title":380},"Voor het derde jaar op rij telde Nederland in 2024 meer openstaande vacatures dan werklozen, blijkt uit nieuwe data van het CBS. In de podcast Verstand van vand",{"id":433,"title":434,"pubDate":435,"logoUrl":360,"thirdParty":10,"orgId":16,"branches":436,"description":438},"3e8d8bef-e495-4233-b3d9-fd79b7e2bca5","Podcast: 'Jongere in veranderende wereld heeft duurzaam onderwijs nodig'","2025-04-23T12:38:11.036+02:00",[437],{"id":370,"title":371},"Vorige week publiceerde de Onderwijsinspectie de Staat van het Onderwijs 2025. In de podcast Verstand van vandaag spreekt Nelleke Jacobs van Leren voor morgen m"]